Sector News

Sandoz launches second digital health competition

October 5, 2018
Life sciences

Novartis’ generics arm Sandoz has launched the second Healthcare Access Challenge (HACk), which is looking to support digital solutions to local healthcare access challenges.

The competition is open to digital technology entrepreneurs and innovators with ideas with the potential to complement or drive new approaches to improving access to healthcare.

Explaining the rationale behind the competition, Sandoz noted that universal access to healthcare “is still arguably the largest unmet medical need and, while great strides continue to be made globally, access challenges vary hugely across geographies and communities”.

It says digital innovation could provide cost-effective and practical solutions with the power to transform access to healthcare.

“There are still two billion people in this world not getting the medicines they need. This is why we are launching Sandoz HACk as we aim to inspire and embrace the brave and innovative thinking of entrepreneurs and visionaries to improve access to healthcare around the world”, said Richard Francis, division head and chief executive of the firm.

The three shortlisted entrants – which will be announced in January next year – will receive support from Sandoz experts to develop their ideas.

By: Seline Mc Kee

Source: Pharma Times

comments closed

Related News

June 3, 2023

Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial

Life sciences

In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.

June 3, 2023

Lonza to acquire Synaffix to strengthen ADC development

Life sciences

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).

June 3, 2023

BD taps Novartis, GSK alum Laura Boros to lead drug delivery device business

Life sciences

In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.

How can we help you?

We're easy to reach